• Allergan Inc., of Irvine, Calif., received a positive opinion from the Irish Medicines Board for use of Botox (botulinum toxin type A) in urinary incontinence in adults with neurogenic detrusor overactivity resulting from spinal cord injury or multiple sclerosis. The drug is approved in the U.S. for a variety of conditions including migraine, upper limb spasticity, cervical dystonia and certain eye muscle problems.

• AMAG Pharmaceuticals Inc.'s board of directors has rebuffed an unsolicited offer from New York-based hedge fund MSMB Capital Management to buy the Lexington, Mass.-based company's outstanding stock for $18 a share in cash in a deal worth about $378 million. The company said the proposal ". . . is not reasonably expected to result in a superior offer to the merger with Allos Therapeutics Inc." and reaffirmed its intention to merge with Allos. That proposed deal – a $686 million all-stock merger with Allos, of Westminster, Colo. – was first announced in July. The company's stock (NASDAQ:AMAG) was down $2.10, or 13.3 percent, to close at $13.72 Monday. (See BioWorld Today, July 21, 2011, and Aug. 4, 2011.)

• BiOasis Technologies Inc., of Vancouver, British Columbia, is using cash and warrants to acquire certain undisclosed intellectual property. The biotech is developing an Alzheimer's disease diagnostic and a drug delivery technology, and the intellectual property relates to the drug delivery side of the business, the company said.

• Huya Bioscience International LLC, of San Diego, formed a partnership with the Shanghai Jiao Tong University School of Pharmacy King's Lab to help the research laboratory accelerate the development of novel drugs to international standards. In exchange, Huya will get access to and first review of therapeutic candidates owned or controlled by King's Lab. No terms were disclosed.

• The Department of Defense Peer Reviewed Medical Research Program awarded NeoStem Inc., of New York, a $1.78 million grant in support of its VSEL technology to treat osteoporosis. VSEL uses very small stem cells found in adult bone marrow that have several physical characteristics generally found in embryonic stem cells.

• Unigene Laboratories Inc., of Boonton, N.J., entered a development services and supply agreement with London-based GlaxoSmithKline plc. The two parties are already partnered on Unigene's oral formulation of a recombinant parathyroid hormone analog for osteoporosis in postmenopausal women. Under the new deal, Unigene will receive $2.2 million in milestone payments for development and manufacturing activities associated with GSK's decision to advance the product into Phase III trials.